BACK

A Phase I, 2-Part Study to evaluate the safety, tolerability, pharmacokinets, and pharmacodynamics of single-ascending doses of intrathecally administered RG6496 in a randomized, placebo-controlled, investigator/participant-blind study with an open-label extension in Huntington's disease gene expansion carriers (POINT-HD)